Position in LGVN
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$91
-$44 QoQ
Shares Held
13
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#36
of 39 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LGVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Allworth Financial LP holds $18,604,480 across 284 Biotechnology names. LGVN ranks #262 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
37,664 | $2,947,961 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,487 | $2,228,827 | |
| 3 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
3,562 | $1,912,615 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,530 | $1,577,556 | |
| 5 | INCY |
Incyte Corp
|
5,182 | $587,431 | |
| 6 | EXEL |
Exelixis, Inc.
|
10,562 | $574,678 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
10,089 | $550,254 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
2,240 | $419,507 |
All Filings in LGVN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $91 | 130 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $135 | 130 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $65 | 130 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $97 | 130 | Shares | Sole | 2025-12-02 | |
| 2025-06-30 | $169 | 130 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||